The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Evaluation of patients, safety, and financial implications of sipuleucel-T (SipT) for treatment of metastatic castrate-resistant prostate cancer (mCRPC): Early real-world experience at USC.
S. Pak
No relevant relationships to disclose
M. Reed
No relevant relationships to disclose
M. Luther
No relevant relationships to disclose
M. Averia
No relevant relationships to disclose
S. Desai
No relevant relationships to disclose
J. K. Pinski
No relevant relationships to disclose
T. B. Dorff
No relevant relationships to disclose
D. I. Quinn
No relevant relationships to disclose
B. Chan
No relevant relationships to disclose